ICER Assessing COVID-19 Treatments Including Fluvoxamine: A Victory for Steve Kirsch’s COVID-19 Early Treatment Fund

ICER Assessing COVID-19 Treatments Including Fluvoxamine: A Victory for Steve Kirsch’s COVID-19 Early Treatment Fund

One of the most influential organizations impacting drug prices that few are aware of is the Institute for Clinical and Economic Review, commonly referred to as “ICER.” The Boston-based independent non-profit wields tremendous clout in America when it comes to the pricing of drugs as many payers look to ICER’s analyses for both a quantitative and qualitative assessment of the underlying value of the drug, tests, or procedures to the patient and broader society. Founded back in 2005 by physician-researcher Steven D. Pearson, MD, MSc, FRCP, the organization primarily focuses on evaluating health care costs rather than therapies. But the organization pivoted and intensified analyses of therapies, diagnostics, and other investigational products, drilling down into cost-effectiveness in a comparable manner to the United Kingdom’s NICE. The pharmaceutical industry hasn’t always been pleased with ICER assessments as the Boston non-profit places an actual monetary value on novel drugs. Thus evermore numbers of payers look to ICER to justify price points. They are funded by Arnold Ventures LLC (formerly the Laura and John Arnold Foundation), pharmaceutical companies, payers, and government...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee